Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
ITM Announces €255m Investment Round, Plans to Advance Radiopharmaceutical Pipeline and to Expand Radioisotope Production Capacities
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, has announced an equity […]
Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical
Telix Pharmaceuticals today announces the successful preclinical development of radiolabelled olaratumab, an antibody licensed from […]
Orbit Discovery and Evergreen Discovery collaborate to discover peptides for targeting radiopharmaceuticals
Evergreen Discovery, a leading radiopharmaceutical drug development company with a focus on the treatment and […]
PeptiDream Announces Nomination of Second Peptide Radiopharmaceutical Therapeutic Development Candidate
PeptiDream, a public Kanagawa, Japan-based biopharmaceutical company, has today announced the nomination of the second […]
Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer
Fusion Pharmaceuticals, a clinical-stage oncology company focused on developing next-generation targeted alpha therapies as precision […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more